{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:33:12Z","timestamp":1793997192395,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijid.2026.108519","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:06:47Z","timestamp":1774958807000},"page":"108519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8069-2368","authenticated-orcid":false,"given":"Dalibor","family":"Vesel\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e1clav","family":"\u010capek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"\u0160anca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Beran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2690-1889","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Sl\u00edva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108519_bib0001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00003495-198632050-00001","article-title":"Inosine pranobex","volume":"32","author":"Campoli-Richards","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2026.108519_bib0002","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s12325-019-00995-6","article-title":"Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases","volume":"36","author":"Sliva","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijid.2026.108519_bib0003","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.3390\/v13112246","article-title":"Inosine pranobex deserves attention as a potential immunomodulator to achieve early alteration of the COVID-19 disease course","volume":"13","author":"Beran","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2026.108519_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-immunol-032712-100001","article-title":"Control of human viral infections by natural killer cells","volume":"31","author":"Jost","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ijid.2026.108519_bib0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.intimp.2016.11.023","article-title":"Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications","volume":"42","author":"Rumel Ahmed","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ijid.2026.108519_bib0006","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/eji.201847948","article-title":"Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression","volume":"50","author":"McCarthy","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2026.108519_bib0007","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3390\/pathogens9121055","article-title":"Inosine pranobex significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic","volume":"9","author":"Beran","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.ijid.2026.108519_bib0008","article-title":"Efficacy and safety of inosine pranobex in COVID-19 patients: a multicenter phase 3 randomized double-blind, placebo-controlled trial","volume":"5","author":"C","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijid.2026.108519_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.01.017","article-title":"Case fatality rates of COVID-19 during epidemic periods of variants of concern: a meta-analysis by continents","volume":"141","author":"Xia","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108519_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.884121","article-title":"Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study","volume":"10","author":"Flacco","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijid.2026.108519_bib0011","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O\u2019Driscoll","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2026.108519_bib0012","doi-asserted-by":"crossref","first-page":"m4509","DOI":"10.1136\/bmj.m4509","article-title":"Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study","volume":"371","author":"Pastor-Barriuso","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108519_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2020.07.029","article-title":"Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis","volume":"99","author":"Zhou","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108519_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.588013","article-title":"Chronic diseases as a predictor for severity and mortality of COVID-19: a systematic review with cumulative meta-analysis","volume":"8","author":"Geng","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0015","unstructured":"\u0160anca O, Jarkovsk\u00fd J, Klika P, Davidov\u00e1 H, Klime\u0161 D, Mu\u017e\u00edk J, et al. P\u0159ehled vyk\u00e1zan\u00fdch t\u0159\u00edznakov\u00fdch diagn\u00f3z dle MKN-10. 2024. https:\/\/www.nzip.cz\/clanek\/1760-prehled-vykazane-triznakove-diagnozy-mkn-10-nrhzs-datovy-souhrn [accessed 30 April 2025]."},{"key":"10.1016\/j.ijid.2026.108519_bib0016","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijid.2026.108519_bib0017","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2337\/dci21-0001","article-title":"Diabetes and COVID-19: population impact 18 months into the pandemic","volume":"44","author":"Gregg","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijid.2026.108519_bib0018","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.medcli.2020.12.017","article-title":"Coronary heart disease and COVID-19: a meta-analysis","volume":"156","author":"Liang","year":"2021","journal-title":"Med Cl\u00edn"},{"key":"10.1016\/j.ijid.2026.108519_bib0019","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ajem.2020.07.009","article-title":"Effect of heart failure on the outcome of COVID-19 \u2014 a meta analysis and systematic review","volume":"46","author":"Yonas","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.20892\/j.issn.2095-3941.2020.0559","article-title":"Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants","volume":"18","author":"Yang","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0021","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/jce.14770","article-title":"Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19","volume":"31","author":"Peltzer","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ijid.2026.108519_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104949","article-title":"Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19\u2013systematic review, meta-analysis, and meta-regression","volume":"29","author":"Pranata","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ijid.2026.108519_bib0023","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1038\/s41598-023-36208-y","article-title":"Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study","volume":"13","author":"Veronese","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.108519_bib0024","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MCP.0000000000000834","article-title":"Chronic obstructive pulmonary disease and COVID-19: interrelationships","volume":"28","author":"Singh","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.101007","article-title":"Peripheral artery disease and COVID-19 outcomes: insights from the Yale DOM-CovX registry","volume":"47","author":"Smolderen","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ijid.2026.108519_bib0026","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41598-022-06276-7","article-title":"Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort","volume":"12","author":"Appelman","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2026.108519_bib0027","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s11684-020-0822-5","article-title":"Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection","volume":"14","author":"Tan","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103743","article-title":"Immunity to SARS-CoV-2 up to 15 months after infection","volume":"25","author":"Marcotte","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ijid.2026.108519_bib0029","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0030","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz","year":"2022","journal-title":"Env Res"},{"key":"10.1016\/j.ijid.2026.108519_bib0032","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12879-022-07418-y","article-title":"SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis","volume":"22","author":"Ssentongo","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2026.108519_bib0033","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108519_bib0034","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2021.19499","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.108519_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"AZ - safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108519_bib0036","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Jansen safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108519_bib0037","unstructured":"Ewopharma International, s.r.o. Isoprinosine 500 mg tablety SmPC. State Institute for Drug Control (S\u00daKL); 2019. https:\/\/prehledy.sukl.cz\/prehledy\/v1\/dokumenty\/12916 [accessed 10 August 2025]."},{"key":"10.1016\/j.ijid.2026.108519_bib0038","unstructured":"Themis Medicare Limited. Viralex SmPC. Rwanda Food and Drug Authority; 2024. https:\/\/rwandafda.gov.rw\/wp-content\/uploads\/2025\/04\/\/VIRALEX-InosinePranobex500mgTablets-SmPC.pdf [accessed 10 August 2025]."},{"key":"10.1016\/j.ijid.2026.108519_bib0039","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir\u2013ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: a retrospective cohort study","volume":"22","author":"Wong","year":"2022","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:05:49Z","timestamp":1793952349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S1201971226001542"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108519","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108519"}}